Parkinson's disease Nervous System Diseases
Conditions
Interventions
The trial is 9 weeks in total. For 4 weeks 1 l of HRW or PLA will be consumed daily (a total of 28 days). There is a 1-week wash-out period, followed by another 4 weeks of 1 l of HRW or PLA daily cons
Sponsors
University of Kent
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. All participants must have a diagnosis of PD by a Neurologist or Geriatrician 2. All participants must be at stage 2 or stage 3 on the Hoehn and Yahr (H&Y) scale. Stage 1 is too mild and stages 4 and 5 could potentially be too severe for appropriate study participation 3. Male or female 4. Able to consume 1 l of HRW or PLA per day 5. All participants' disease should be in a stable state for the past 2 months
Exclusion criteria
Exclusion criteria: 1. Participants whose Parkinson’s is not controlled. 2. Participants who are at stage 1, stage 4 and stage 5 of the H&Y scale. 3. Participants who cannot consent for themselves.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function and manual dexterity to be measured using a Purdue Pegboard Test (the three-trial administration test-retest will be used to increase reliability) at baseline, after 1 week, after 4 weeks of HRW and PLA consumption. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measures 1-4 will be assessed at time points of: baseline, week 1, week 4, week 5, week 6, week 9: 1.Transient mood measured using a Profile of Mood States (POMS)– Short Form. 2. Visual attention measured using The Flanker Compatibility Task 3. The burden of non-motor symptoms, including non-motor fluctuations, using the Movement Disorder Society Non-Motor Rating Scale 4. Blood markers of oxidative stress, inflammation/neuro inflammation and BDNF will measured in serum or plasma derived from venous blood samples. 5. Physical activity levels will be measured using an activity tracker worn for a total of eight weeks. | — |
Countries
England, United Kingdom
Outcome results
None listed